An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) will release its third quarter 2021 financial results on Thursday, November 4, 2021, before the market opens. Following this, a live conference call will take place at 8:30 a.m. EDT for analysts and investors to discuss the results and provide corporate updates. Atara is recognized for its innovative T-cell immunotherapy platform focused on treating cancers and autoimmune diseases, with lead programs in advanced clinical development, particularly targeting Epstein-Barr virus-related ailments.
Positive
Lead program in Phase 3 clinical development for EBV-driven post-transplant lymphoproliferative disease.
Leveraging an advanced allogeneic EBV T-cell platform aimed at high unmet medical needs.
Negative
None.
Live Conference Call and Webcast at 8:30 a.m. EDT
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2021 financial results before market open on Thursday, November 4, 2021. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. EDT to discuss the Company’s financial results and provide a corporate update.
Analysts and investors can participate in the conference call by dialing 888-437-3179 for domestic callers and 862-298-0702 for international callers, using the conference ID 13723551. A live audio webcast can be accessed by visiting the Investors & Media – News & Events section of atarabio.com. An archived replay will be available on the Company's website for 30 days following the live webcast.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel® in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.
When will Atara Biotherapeutics release its third quarter 2021 financial results?
Atara Biotherapeutics will release its third quarter 2021 financial results before the market opens on Thursday, November 4, 2021.
What time is Atara Biotherapeutics' conference call on November 4, 2021?
The conference call for Atara Biotherapeutics will be held at 8:30 a.m. EDT on November 4, 2021.
What is the primary focus of Atara Biotherapeutics?
Atara Biotherapeutics specializes in T-cell immunotherapy to develop treatments for cancer and autoimmune diseases, particularly using its EBV T-cell platform.
How can investors participate in Atara Biotherapeutics' conference call?
Investors can participate by dialing 888-437-3179 for domestic calls or 862-298-0702 for international calls, using conference ID 13723551.
